Why will it never be known if convalescent plasma is effective for COVID-19
High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion crit...
Main Authors: | Manuel Rojas, Juan-Manuel Anaya |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Journal of Translational Autoimmunity |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589909020300368 |
Similar Items
-
Facts and challenges in convalescent plasma therapy in COVID-19
by: Kumar H
Published: (2020-12-01) -
Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial
by: Philippe Bégin, et al.
Published: (2021-05-01) -
Convalescent plasma: A potential therapeutic option for COVID-19 patients
by: Swee Li Ng, et al.
Published: (2020-01-01) -
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
by: Focosi Daniele, et al.
Published: (2021-01-01) -
Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions
by: Jayanth Seshan, et al.
Published: (2020-09-01)